Around 375 patients with #chronicmyeloidleukaemia (CML) in El Salvador, Indonesia & the Philippines are now accessing quality-assured generic #nilotinib.

Made possible through a #voluntarylicence from @novartis.bsky.social to MPP via the ATOM coalition - @uiccofficial.bsky.social!

lnkd.in/eruiP-Gv

Apotex Launches Nilotinib Capsules: First Generic Tasigna® in the U.S. Market Apotex Corp. has launched nilotinib capsules, the first generic version of Tasigna® in the U.S., enhancing access to critical leukemia treatment.

Apotex Launches Nilotinib Capsules: First Generic Tasigna® in the U.S. Market #United_States #Apotex #nilotinib #Tasigna #Weston,_Florida

🎉 Congrats to Dr. Reddy's Lab for receiving tentative USFDA approval for their generic version of #nilotinib, used to treat chronic myeloid #leukaemia!
✅This milestone makes them 2️⃣ of 4️⃣ MPP sublicensees to achieve this, enhancing access to affordable cancer treatment in #LMICs.
🔗 bit.ly/3Yma62r

🌍🎗️ This #WorldCancerDay, let's raise awareness about #ChronicMyeloidLeukaemia & the importance of accessible treatments.
📺✨Watch Prof. Zeba Aziz as she discusses the impact of #nilotinib & the efforts to make life-saving medicines available to all. #UnitedByUnique
🔗 youtu.be/UKmvGMnQHT0?...

FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment - OncoDaily FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment / Access to Oncology Medicines Coalition, cancer, chronic myeloid

FDA Approves Generic Nilotinib: Expanding Access to Chronic Myeloid Leukemia Treatment
@fda.gov

oncodaily.com/drugs/niloti...

#AccessToOncology #MedicinesCoalition #Cancer #Medicine #ChronicMyeloidLeukemia #CML #CMLTreatment #FDA #Health #Nilotinib #OncoDaily #Oncology #UICC #TheMaxFoundation

MPP, ATOM, IDA Foundation, and Max Welcome FDA Approval for Hetero's Generic Nilotinib - MPP Geneva – The Medicines Patent Pool (MPP), the Access to Oncology Medicines Coalition (ATOM Coalition), IDA Foundation, and The Max Foundation (Max) are thrilled to report that MPP sublicensee Hetero h...

📣MPP, ATOM Coalition, IDA Foundation & The Max Foundation announce FDA approval for Hetero's generic #nilotinib for chronic myeloid #leukaemia (#CML).
🎉This milestone enhances access to #cancer treatment options in LMICs.
📃Read our joint statement > bit.ly/3ZA1pBj
#CancerTreatment #GlobalHealth